Early recovery with Cerebrolysin

Effective pharmacological treatment for STROKE patients

Muresanu D.F. et al., Cerebrolysin And Recovery after Stroke (CARS), Stroke 2016; 47:151-159

CARS results - Cerebrolysin in patients after STROKE

- Improvement of motor functions
- Early recovery
- Regain full independence
- Increase quality of life
Early therapeutic success after 14 days with Cerebrolysin

→ Patients are less dependent on caregivers early on
→ Strong decline in patient’s post-stroke depression

**Figure**: Treatment effects (Mann-Whitney) in the ARAT* score

- **Superiority** of Cerebrolysin already after 14 days
- **Large treatment** effect at day 90 – **significant recovery**
- Fast and long-term effects in the Cerebrolysin group

---

**Table**: Cerebrolysin And Recovery after Stroke (CARS) – A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial

<table>
<thead>
<tr>
<th>Patients</th>
<th>104 Cerebrolysin group + 104 Placebo group = 208 patients in total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebrolysin group = Cerebrolysin + Standard rehabilitation therapy</td>
<td></td>
</tr>
<tr>
<td>Placebo group = Saline + Standard rehabilitation therapy</td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td>30ml/day for 21 days followed by 69 days treatment-free period</td>
</tr>
<tr>
<td>Primary endpoint</td>
<td>ARAT* score on day 90</td>
</tr>
</tbody>
</table>

---

Published in

Stroke

Stroke. January 2016;47:151-159
Muresanu D.F. et al.

---


**ABBREVIATED PRESCRIBING INFORMATION.** Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of porcine brain-derived peptide preparation (Cerebrolysin concentrate) in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: Organic, metabolic and neurodegenerative disorders of the brain, especially senile dementia of Alzheimer’s type - Post-apoplectic complications - Cranio-cerebral trauma; post-operative trauma, cerebral contusion or concussion. Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.

Copyright © 2016 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria

CERE/A/01/2016/7